193 related articles for article (PubMed ID: 32363582)
1. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
2. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B.
Zhou L; Li X; Huang X; Chen L; Gu L; Huang Y
J Viral Hepat; 2019 Jul; 26(7):795-802. PubMed ID: 30578715
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
4. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
[TBL] [Abstract][Full Text] [Related]
5. [Observation of PD-1
He J; Yao YQ; Xia RX; Qiu TJ; Long L; Wang Y; Jiang Y
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):316-322. PubMed ID: 35462489
[No Abstract] [Full Text] [Related]
6. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment.
Tan N; Luo H; Kang Q; Pan J; Cheng R; Xi H; Chen H; Han Y; Yang Y; Xu X
Virus Res; 2022 Feb; 309():198660. PubMed ID: 34929214
[TBL] [Abstract][Full Text] [Related]
7. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.
Huang R; Yang CC; Liu Y; Xia J; Su R; Xiong YL; Wang GY; Sun ZH; Yan XM; Lu S; Wu C
World J Gastroenterol; 2015 Sep; 21(34):9957-65. PubMed ID: 26379400
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
9. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
11. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.
Li N; Zhou Z; Li F; Sang J; Han Q; Lv Y; Zhao W; Li C; Liu Z
Oncotarget; 2017 Jul; 8(28):46020-46033. PubMed ID: 28545019
[TBL] [Abstract][Full Text] [Related]
12. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
13. [Significance of soluble PD-L1 in patients with chronic hepatitis B and hepatitis C].
Ke RM; Ouyang LJ; Li WF; Peng XM
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):133-137. PubMed ID: 37137827
[No Abstract] [Full Text] [Related]
14. Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B.
Chu YJ; Jeng WJ; Pan MH; Hu HH; Luo WS; Su CY; Chiang CT; Jen CL; Chen CJ; Yang HI
J Gastroenterol; 2022 Jun; 57(6):423-432. PubMed ID: 35459967
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B.
Wenjin Z; Chuanhui P; Yunle W; Lateef SA; Shusen Z
BMC Gastroenterol; 2012 Aug; 12():109. PubMed ID: 22894700
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
17. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.
Cheng HY; Kang PJ; Chuang YH; Wang YH; Jan MC; Wu CF; Lin CL; Liu CJ; Liaw YF; Lin SM; Chen PJ; Lee SD; Yu MW
PLoS One; 2014; 9(11):e95870. PubMed ID: 25427199
[TBL] [Abstract][Full Text] [Related]
18. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
19. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
20. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
